College Stock: Penny Stock News

The Dean’s film for $VRAL is in production stage and because it’s so forward-looking that it’s in the future, The Dean thinks it’s very likely to get as much attention as some controversial AIDS public service announcements out there today.

Although advancements in drug treatments have given HIV and AIDS patients the possibility to extend their lives by 2o years, there’s no cost effective treatment and cure out there.

That’s why The Dean thinks $VRAL has extraordinary potential to cure AIDS in Africa and every corner of the globe.

The AIDS Treatment Activists Coalition recently graded companies like Merck (NYSE: MRK), after a year long study of AIDS treatments. Merck (NYSE: MRK) scored the highest of the 9 companies in the study but overall the companies only achieved a C minus average.

The Dean and his students know that grade just won’t do and that’s why The Dean thinks there’s plenty of room for $VRAL in this market.

And who better than the pioneer of HIV/AIDS research, Dr. Luc Montagnier, to lead a team to fight this virus across the world. Dr. Montagnier doesn’t work at Merck (NYSE: MRK) or Pfizer (NYSE: PFE); he works at $VRAL! This is just another reason why $VRAL‘s made The Dean’s List.

The 1 million people infected in the United States is said to make up only 3% of the world’s HIV/AIDS population. Avert.org, an international AIDS charity, reports that approximately 33 million people are infected worldwide and many others are walking around not knowing that they’re infected.

The Dean’s $VRAL video will show how their VGV-1 injectable drug could change everything.

Countries like South Africa, Nigeria and India house the world’s largest HIV/AIDS populations but the virus is EVERYWHERE. The Dean has done his homework and thinks it’s insane that 95% of the world’s infected population lives in the developing world where health care and government funding are lacking.

$VRAL has already conducted initial clinical trails in countries like China, Mexico and Bulgaria and have received positive results in 3 phases of trials in South Africa where HIV/AIDS drugs are desperately needed.

Since 1981, 25 million people have died from AIDS around the world, which means that nearly 900,000 people die every year because there’s no cure for the infected masses.

The Dean wants his students to do their homework to see for themselves that 70% of people with HIV/AIDS will die because they do not have access to treatment.

$VRAL and their VGV-1 injectable drug fall into the $8 billion HIV drug market, which is expected to GROW 50% to $12 billion by 2016. With more than 33 million people infected worldwide, The Dean believes $VRAL can change the world with their drug treatment and have already conducted 5 successful human trials outside the United States.

The Dean’s not a medical expert but he plans to show the world why $VRAL deserves an A+.